Minkwan Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minkwan Kim has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- In Hyun Jung
Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin-si, Republic of Korea
8 shared publications - Jae-Sun Uhm
Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
4 shared publications - Seung-Pyo Lee
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - SungA Bae
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Republic of Korea
4 shared publications - Hyung-Kwan Kim
Seoul National University Hospital
3 shared publications - Je-Wook Park
Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea
3 shared publications
Latest Publications
- 21 September 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- p. e014345
Clonal Hematopoiesis of Indeterminate Potential Proteomic Risk Score for Predicting Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is common in heart failure with preserved ejection fraction (HFpEF). However, the proteomic signatures linked to CHIP driver mutations and their prognostic implications in HFpEF remain poorly defined. We aimed to identify plasma protein signatures associated with CHIP driver mutations and to develop and externally validate a CHIP-proteomic risk score (CHIP-ProtRS) for predicting clinical outcomes in HFpEF. METHODS: The derivation cohort consisted of 118 TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) participants with available CHIP sequencing and proteomic profiling using the SomaScan platform. Associations between CHIP mutations and circulating proteins were assessed using gene-specific linear regression adjusted for age, with correction for multiple comparisons. Significant proteins were used to derive gene-specific proteomic classifiers using nested cross-validated least absolute shrinkage and selection operator logistic regression. A composite CHIP-ProtRS was generated using least absolute shrinkage and selection operator Cox regression and validated in a composite of 3 independent HFpEF cohorts (n=654). The primary end point was a composite of death and HF hospitalization. RESULTS: In TOPCAT, 30.5% of tested participants carried ≥1 CHIP mutation. Significant protein associations were identified for TET2 (7 proteins), DNMT3A (10), and PPM1D (5), all of which were enriched in immune and inflammatory pathways. Gene-specific least absolute shrinkage and selection operator models showed good discrimination for CHIP mutation (area under the curves, 0.752–0.898). The primary end point occurred in 28.0% of the derivation cohort and 34.7% of the validation cohorts. In the Cox-least absolute shrinkage and selection operator combination, only the TET2 -derived proteomic signature retained a nonzero coefficient in the CHIP-ProtRS. The CHIP-ProtRS was independently associated with the primary end point after adjustment for age, sex, Meta-Analysis Global Group in Chronic Heart Failure score, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and atrial fibrillation in the derivation (adjusted hazard ratio, 1.42 [95% CI, 1.01–2.00]) and validation cohorts (adjusted hazard ratio, 1.16 [95% CI, 1.01–1.32]). CONCLUSIONS: CHIP is associated with alterations in plasma concentrations of immune/inflammatory proteins. A CHIP-ProtRS is independently associated with adverse outcomes in HFpEF, supporting its potential role as a biomarker of risk and underlying pathobiology.
- 21 September 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- p. e014345
Clonal Hematopoiesis of Indeterminate Potential Proteomic Risk Score for Predicting Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is common in heart failure with preserved ejection fraction (HFpEF). However, the proteomic signatures linked to CHIP driver mutations and their prognostic implications in HFpEF remain poorly defined. We aimed to identify plasma protein signatures associated with CHIP driver mutations and to develop and externally validate a CHIP-proteomic risk score (CHIP-ProtRS) for predicting clinical outcomes in HFpEF. METHODS: The derivation cohort consisted of 118 TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) participants with available CHIP sequencing and proteomic profiling using the SomaScan platform. Associations between CHIP mutations and circulating proteins were assessed using gene-specific linear regression adjusted for age, with correction for multiple comparisons. Significant proteins were used to derive gene-specific proteomic classifiers using nested cross-validated least absolute shrinkage and selection operator logistic regression. A composite CHIP-ProtRS was generated using least absolute shrinkage and selection operator Cox regression and validated in a composite of 3 independent HFpEF cohorts (n=654). The primary end point was a composite of death and HF hospitalization. RESULTS: In TOPCAT, 30.5% of tested participants carried ≥1 CHIP mutation. Significant protein associations were identified for TET2 (7 proteins), DNMT3A (10), and PPM1D (5), all of which were enriched in immune and inflammatory pathways. Gene-specific least absolute shrinkage and selection operator models showed good discrimination for CHIP mutation (area under the curves, 0.752–0.898). The primary end point occurred in 28.0% of the derivation cohort and 34.7% of the validation cohorts. In the Cox-least absolute shrinkage and selection operator combination, only the TET2 -derived proteomic signature retained a nonzero coefficient in the CHIP-ProtRS. The CHIP-ProtRS was independently associated with the primary end point after adjustment for age, sex, Meta-Analysis Global Group in Chronic Heart Failure score, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and atrial fibrillation in the derivation (adjusted hazard ratio, 1.42 [95% CI, 1.01–2.00]) and validation cohorts (adjusted hazard ratio, 1.16 [95% CI, 1.01–1.32]). CONCLUSIONS: CHIP is associated with alterations in plasma concentrations of immune/inflammatory proteins. A CHIP-ProtRS is independently associated with adverse outcomes in HFpEF, supporting its potential role as a biomarker of risk and underlying pathobiology.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4)
Proteomic Risk Score for Prediction of Incident Hypertension
BACKGROUND: Proteomic signatures may enhance the prediction of cardiometabolic diseases for targeted prevention. We evaluated whether a proteomic risk score (ProtRS) improves the prediction of incident hypertension. METHODS: Within the UK Biobank Proteomics data set, participants at risk for incident hypertension were randomly split into derivation (n=25 158) and test (n=10 781) sets. A ProtRS was trained in the derivation cohort using least absolute shrinkage and selection operator penalized Cox regression and evaluated in the test set with sequential adjustment for demographics, clinical risk factors, and a polygenic risk score (PRS). External replication was performed in the Asklepios study (n=793). RESULTS: In UK Biobank Proteomics (2312 events), each 1-SD higher ProtRS was associated with incident hypertension after covariate adjustment (hazard ratio, 1.68 [95% CI, 1.59–1.78]; P 2 from 1733 to 2048, P P 2 (from 120.4 to 132.4; P <0.001), C-index (from 0.723 to 0.736) and discrimination (net reclassification improvement, 13.1% [95% CI, 1.2%–24.1%]). Pathway analysis highlighted neutrophil degranulation, insulin-like growth factor, PI3K signaling, and extracellular matrix remodeling. CONCLUSIONS: A ProtRS improves prediction of incident hypertension beyond demographics, clinical, and genetic information in UK Biobank Proteomics, with supportive external replication. Proteomic information may enhance individualized hypertension risk stratification and provide biologic insights into disease development.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4)
Proteomic Risk Score for Prediction of Incident Hypertension
BACKGROUND: Proteomic signatures may enhance the prediction of cardiometabolic diseases for targeted prevention. We evaluated whether a proteomic risk score (ProtRS) improves the prediction of incident hypertension. METHODS: Within the UK Biobank Proteomics data set, participants at risk for incident hypertension were randomly split into derivation (n=25 158) and test (n=10 781) sets. A ProtRS was trained in the derivation cohort using least absolute shrinkage and selection operator penalized Cox regression and evaluated in the test set with sequential adjustment for demographics, clinical risk factors, and a polygenic risk score (PRS). External replication was performed in the Asklepios study (n=793). RESULTS: In UK Biobank Proteomics (2312 events), each 1-SD higher ProtRS was associated with incident hypertension after covariate adjustment (hazard ratio, 1.68 [95% CI, 1.59–1.78]; P 2 from 1733 to 2048, P P 2 (from 120.4 to 132.4; P <0.001), C-index (from 0.723 to 0.736) and discrimination (net reclassification improvement, 13.1% [95% CI, 1.2%–24.1%]). Pathway analysis highlighted neutrophil degranulation, insulin-like growth factor, PI3K signaling, and extracellular matrix remodeling. CONCLUSIONS: A ProtRS improves prediction of incident hypertension beyond demographics, clinical, and genetic information in UK Biobank Proteomics, with supportive external replication. Proteomic information may enhance individualized hypertension risk stratification and provide biologic insights into disease development.
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e042800
Clinical Usefulness of Left Ventricular Global Longitudinal Strain as a Predictor of Prognosis in Patients With Acute Ischemic Stroke (GLS‐STROKE Study)
Background: The prognostic role of left ventricular global longitudinal strain (LV‐GLS) in acute ischemic stroke (AIS) remains unexplored despite its established value in cardiovascular conditions. We aimed to investigate the prognostic value of LV‐GLS in patients with AIS. Methods: In this prospective cohort study, 698 patients with AIS (mean age, 67.6±13.8 years; 60.2% men) underwent transthoracic echocardiography using speckle‐tracking to measure LV‐GLS within 7 days of admission. The primary end points included all‐cause death and recurrent ischemic stroke, with a 3‐month modified Rankin Scale score ≥3 considered a poor outcome. Results: Over a median follow‐up of 593 days, the primary end point occurred in 65 patients (9.3%), with significant differences in LV‐GLS between those reaching the end point (16.3%) and the others (19.1%; P P 2 and continuous net reclassification index analyses (0.25 [95% CI, 0.01–0.42]; P =0.044). Subgroup analysis revealed the prognostic relevance of LV‐GLS irrespective of atrial fibrillation status. In predicting a poor functional outcome, LV‐GLS also provided incremental value over traditional risk factors and the initial National Institutes of Health Stroke Scale score (continuous net reclassification index, 0.27 [95% CI, 0.09–0.45]; P =0.004). Conclusions: LV‐GLS is a robust predictor of cardiocerebrovascular outcomes in AIS and offers incremental prognostic value beyond traditional risk factors. Incorporating LV‐GLS into AIS management may help identify high‐risk patients and guide intensive monitoring strategies. Registration: URL: https://trialsearch.who.int . Unique identifier: KCT0005780.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e042800
Open AccessClinical Usefulness of Left Ventricular Global Longitudinal Strain as a Predictor of Prognosis in Patients With Acute Ischemic Stroke (GLS‐STROKE Study)
Background: The prognostic role of left ventricular global longitudinal strain (LV‐GLS) in acute ischemic stroke (AIS) remains unexplored despite its established value in cardiovascular conditions. We aimed to investigate the prognostic value of LV‐GLS in patients with AIS. Methods: In this prospective cohort study, 698 patients with AIS (mean age, 67.6±13.8 years; 60.2% men) underwent transthoracic echocardiography using speckle‐tracking to measure LV‐GLS within 7 days of admission. The primary end points included all‐cause death and recurrent ischemic stroke, with a 3‐month modified Rankin Scale score ≥3 considered a poor outcome. Results: Over a median follow‐up of 593 days, the primary end point occurred in 65 patients (9.3%), with significant differences in LV‐GLS between those reaching the end point (16.3%) and the others (19.1%; P P 2 and continuous net reclassification index analyses (0.25 [95% CI, 0.01–0.42]; P =0.044). Subgroup analysis revealed the prognostic relevance of LV‐GLS irrespective of atrial fibrillation status. In predicting a poor functional outcome, LV‐GLS also provided incremental value over traditional risk factors and the initial National Institutes of Health Stroke Scale score (continuous net reclassification index, 0.27 [95% CI, 0.09–0.45]; P =0.004). Conclusions: LV‐GLS is a robust predictor of cardiocerebrovascular outcomes in AIS and offers incremental prognostic value beyond traditional risk factors. Incorporating LV‐GLS into AIS management may help identify high‐risk patients and guide intensive monitoring strategies. Registration: URL: https://trialsearch.who.int . Unique identifier: KCT0005780.
- Open Access
- 19 November 2025
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 14 (1) , 102355
Vitis vinifera seed extract reduces venous reflux time in patients with varicose veins: VICTORY randomized controlled trial
- 19 November 2025
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 14 (1) , 102355
Open AccessVitis vinifera seed extract reduces venous reflux time in patients with varicose veins: VICTORY randomized controlled trial
- 1 October 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (10) , 1719-1730
Impact of Emergency Medical Services Call–to–Hospital Arrival Time on Outcomes of Cardiac Arrest: A Nationwide Prospective Cohort
- 1 October 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (10) , 1719-1730
Impact of Emergency Medical Services Call–to–Hospital Arrival Time on Outcomes of Cardiac Arrest: A Nationwide Prospective Cohort
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e042003
Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
Background: The recent reclassification of steatotic liver disease into metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated alcohol‐related liver disease has highlighted their potential cardiovascular implications. This study aimed to investigate the impact of MASLD and metabolic dysfunction‐associated alcohol‐related liver disease on the risk of newly diagnosed atrial fibrillation (AF). Methods: Data from 362 285 participants who underwent a health screening in 2009 to 2010, sourced from the Korean National Health Insurance database, were identified, and we retrospectively analyzed their data through 2019. Excluding those with other liver diseases and heavy alcoholics, 206 455 participants with a fatty liver index were included. The primary outcome was newly diagnosed AF; associated conditions, such as ischemic stroke and heart failure, were also investigated. Participants were classified into 4 groups based on their steatotic liver disease status and alcohol consumption levels. Results: Over a median follow‐up of 9.6 years, 5335 participants were newly diagnosed with AF (2.74 per 1000 person‐years). The risk of AF was significantly higher in patients with MASLD who did not consume alcohol (adjusted hazard ratio [aHR], 1.32 [95% CI, 1.23–1.41]; P P P =0.011). Conclusions: MASLD is associated with incident AF. These findings suggest that metabolic dysfunction plays a more significant role in AF occurrence than the direct toxic effects of alcohol.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e042003
Open AccessMetabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
Background: The recent reclassification of steatotic liver disease into metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated alcohol‐related liver disease has highlighted their potential cardiovascular implications. This study aimed to investigate the impact of MASLD and metabolic dysfunction‐associated alcohol‐related liver disease on the risk of newly diagnosed atrial fibrillation (AF). Methods: Data from 362 285 participants who underwent a health screening in 2009 to 2010, sourced from the Korean National Health Insurance database, were identified, and we retrospectively analyzed their data through 2019. Excluding those with other liver diseases and heavy alcoholics, 206 455 participants with a fatty liver index were included. The primary outcome was newly diagnosed AF; associated conditions, such as ischemic stroke and heart failure, were also investigated. Participants were classified into 4 groups based on their steatotic liver disease status and alcohol consumption levels. Results: Over a median follow‐up of 9.6 years, 5335 participants were newly diagnosed with AF (2.74 per 1000 person‐years). The risk of AF was significantly higher in patients with MASLD who did not consume alcohol (adjusted hazard ratio [aHR], 1.32 [95% CI, 1.23–1.41]; P P P =0.011). Conclusions: MASLD is associated with incident AF. These findings suggest that metabolic dysfunction plays a more significant role in AF occurrence than the direct toxic effects of alcohol.
- Open Access
- 8 January 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (2) , 101534
Exploring the Impact of Clonal Hematopoiesis on Heart Failure and Remodeling in Aortic Stenosis
- 8 January 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (2) , 101534
Open AccessExploring the Impact of Clonal Hematopoiesis on Heart Failure and Remodeling in Aortic Stenosis
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (5) , e21
Evaluation of Burnout and Contributing Factors in Imaging Cardiologists in Korea
Choi YJ, et al. J Korean Med Sci. 2024 Nov;40:e21. https://doi.org/10.3346/jkms.2025.40.e21
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (5) , e21
Open AccessEvaluation of Burnout and Contributing Factors in Imaging Cardiologists in Korea
Choi YJ, et al. J Korean Med Sci. 2024 Nov;40:e21. https://doi.org/10.3346/jkms.2025.40.e21
- Open Access
- 25 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0314305
Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), have shown benefits in patient with heart failure (HF), however, adherence remains a significant issue: with only 60% of patients continuing usage beyond a year. This study aims to identify patients at risk of discontinuing SGLT2i and promote its judicious use to reduce hospitalizations and improve cardiovascular outcomes. Using the Korean National Health Insurance Service database, patients diagnosed with HF and diabetes mellitus (n = 1,665,565) between 2013 and 2018 were identified. Among them, 55,694 participants prescribed SGLT2i were enrolled. The primary endpoint included 1) all-cause mortality and 2) SGLT2i-related hospitalization, encompassing incidents such as ketoacidosis, acute kidney injury, urinary tract infections, fall-related fractures, and other unplanned hospitalizations. During the follow-up period (median: 2.3 years; range: 1.2–3.6 years), 8,463 participants reached the primary endpoint (25.5 for all-cause death and 39.4 for SGLT2i-related hospitalizations per 1,000 person-years). Independent risk factors for the primary endpoint in multivariate Cox regression and propensity-score matching analyses included age of ≥ 70 years, body mass index (BMI) 2, body weight pp<0.001). Old age, low weight or BMI, and the use of diuretics are risk factors that hinder the continuous use of SGLT2i in diabetic patients with HF. Close monitoring for side effects is essential when prescribing SGLT2i, particularly for those with multiple risk factors.
- 25 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0314305
Open AccessRisk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), have shown benefits in patient with heart failure (HF), however, adherence remains a significant issue: with only 60% of patients continuing usage beyond a year. This study aims to identify patients at risk of discontinuing SGLT2i and promote its judicious use to reduce hospitalizations and improve cardiovascular outcomes. Using the Korean National Health Insurance Service database, patients diagnosed with HF and diabetes mellitus (n = 1,665,565) between 2013 and 2018 were identified. Among them, 55,694 participants prescribed SGLT2i were enrolled. The primary endpoint included 1) all-cause mortality and 2) SGLT2i-related hospitalization, encompassing incidents such as ketoacidosis, acute kidney injury, urinary tract infections, fall-related fractures, and other unplanned hospitalizations. During the follow-up period (median: 2.3 years; range: 1.2–3.6 years), 8,463 participants reached the primary endpoint (25.5 for all-cause death and 39.4 for SGLT2i-related hospitalizations per 1,000 person-years). Independent risk factors for the primary endpoint in multivariate Cox regression and propensity-score matching analyses included age of ≥ 70 years, body mass index (BMI) 2, body weight pp<0.001). Old age, low weight or BMI, and the use of diuretics are risk factors that hinder the continuous use of SGLT2i in diabetic patients with HF. Close monitoring for side effects is essential when prescribing SGLT2i, particularly for those with multiple risk factors.
- Open Access
- 11 October 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04210
Socioeconomic disparities and cardio-cerebrovascular diseases: A nationwide cross-sectional study
Cardio-cerebrovascular diseases (CCVDs), including ischaemic heart disease and stroke, are the most common cause of death worldwide, according to the World Health Organization [1]. This trend continues to persist today [2]. Traditionally, hypertension, diabetes mellitus, dyslipidaemia, obesity, smoking, alcohol consumption, and lack of physical activity have been recognised as risk factors for CCVD [3]. Relatedly, […]
- 11 October 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04210
Open AccessSocioeconomic disparities and cardio-cerebrovascular diseases: A nationwide cross-sectional study
Cardio-cerebrovascular diseases (CCVDs), including ischaemic heart disease and stroke, are the most common cause of death worldwide, according to the World Health Organization [1]. This trend continues to persist today [2]. Traditionally, hypertension, diabetes mellitus, dyslipidaemia, obesity, smoking, alcohol consumption, and lack of physical activity have been recognised as risk factors for CCVD [3]. Relatedly, […]